NCT04371016

Brief Summary

Acute respiratory distress syndrome (ARDS) is defined using the clinical criteria of bilateral pulmonary opacities on a chest radiograph, arterial hypoxemia (partial pressure of arterial oxygen \[PaO2\] to fraction of inspired oxygen \[FiO2\] ratio ≤ 300 mmHg with positive end-expiratory pressure \[PEEP\] ≥ 5 cmH2O) within one week of a clinical insult or new or worsening respiratory symptoms, and the exclusion of cardiac failure as the primary cause. ARDS is a fatal condition for intensive care unit (ICU) patients with a mortality between 30 and 40%, and a frequently under-recognized challenge for clinicians. Patients with severe symptoms may retain sequelae that have recently been reported in the literature. These sequelae may include chronic respiratory failure, disabling neuro-muscular disorders, and post-traumatic stress disorder identical to that observed in soldiers returning from war. The management of a patient with ARDS requires first of all an optimization of oxygenation, which relies primarily on mechanical ventilation, whether invasive or non-invasive (for less severe patients). Since the ARDS network study published in 2000 in the New England Journal of Medicine, it has been internationally accepted that tidal volumes must be reduced in order to limit the risk of alveolar over-distension and ventilator-induced lung injury (VILI). A tidal volume of approximately 6 mL.kg-1 ideal body weight (IBW) should be applied. Routine neuromuscular blockade of the most severe patients (PaO2/FiO2 \< 120 mmHg) is usually the rule, although it is increasingly being questioned. Comprehensive ventilatory management is based on the concepts of baby lung and open lung, introduced respectively by Gattinoni and Lachmann. According to these concepts, it must be considered that the lung volume available for mechanical ventilation is very small compared to the healthy lung for a given patient (baby lung) and that the reduction in tidal volume must be associated with the use of sufficient PEEP and alveolar recruitment maneuvers to keep the lung "open" and limit the formation of atelectasis. In addition to this optimization of mechanical ventilation, it is possible to reduce the impact of mechanical stress on the lung. The prone position, for example, makes it possible to free from certain visceral and mediastinal constraints, to optimize the distribution of ventilation as well as the ventilation to perfusion ratios. Thanks to the technological progress of intensive care beds, it is now possible to verticalize ventilated and sedated patients in complete safety. Verticalization could reduce the constraints imposed to the lungs, by reproducing the more physiological vertical station, and thus modifying the distribution of ventilation. Indeed, in two physiological studies published in 2006 and 2013 in Intensive Care Medicine, 30 to 40% of patients with ARDS appeared to respond to partial body verticalization at 45° and 60° (in a semi-seated or seated position). In addition to improving arterial oxygenation, verticalization appeared to decrease ventilatory stress, related to supine position, and increase alveolar recruitment, with improved lung compliance and end-expiratory lung volume (EELV) over time. Nevertheless, 90° verticalization has never been studied, nor have positions without body flexion (seated or semi-seated). In these studies, only patients with the highest lung compliance appeared to respond. These data support the current hypothesis of subgroups of patients with ARDS with different pathophysiological characteristics (morphological and phenotypic) and therapeutic responses. The investigators hypothesize that verticalization of patients with ARDS improves ventilatory mechanics by reducing the constraints imposed on the lung (transpulmonary pressure), pulmonary aeration, arterial oxygenation and ventilatory parameters. The first objective is to study the influence of the bed position of the patient with early ARDS on the variations in respiratory mechanics represented by the transpulmonary driving pressure (ΔPtp). The second objective is to evaluate changes in ventilatory physiology, tolerance and feasibility of verticalization in patients with early ARDS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 30, 2020

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

April 24, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 1, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 14, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 14, 2021

Completed
Last Updated

August 25, 2021

Status Verified

June 1, 2020

Enrollment Period

10 months

First QC Date

April 24, 2020

Last Update Submit

August 24, 2021

Conditions

Keywords

Acute Respiratory Distress SyndromeMechanical VentilationVerticalizationIntensive Care Unit

Outcome Measures

Primary Outcomes (1)

  • Transpulmonary driving pressure (ΔPtp)

    Difference between the transpulmonary driving pressure (ΔPtp) measured at the end of each verticalization step (30th minute) and the basal value measured at the beginning of the protocol, in strict dorsal decubitus (0°).

    At the end of each verticalization step (30th minute)

Secondary Outcomes (70)

  • Pulmonary mechanics

    Baseline

  • Pulmonary mechanics

    At the end of each verticalization step (30th minute)

  • Pulmonary mechanics

    Baseline

  • Pulmonary mechanics

    At the end of each verticalization step (30th minute)

  • Pulmonary mechanics

    Baseline

  • +65 more secondary outcomes

Study Arms (1)

Verticalization group

EXPERIMENTAL

After checking the availability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB), the inclusion and non-inclusion criteria, as well as the morphology of lung injury, the patient is included. The following procedures are performed : * insertion of an esophageal balloon catheter (Nutrivent®, Sidam) * installation of an EIT belt in the 4th or 5th intercostal space (Pulmovista® 500, Dräger) * insertion of a Swan-Ganz catheter * continuous recording of digital and analogic data After collecting initial data from the patient in a strict lying position at 0°, successive 30-minutes position steps at 30°, 60° and 90° will be performed. At the end of the 30 minutes, and for each step, all the data is collected.

Other: Verticalization (bed)

Interventions

The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes. At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method

Verticalization group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with moderate or severe Acute Respiratory Distress Syndrome (ARDS) (PaO2/FiO2 \< 200 mmHg), at their early phase (\< 12h), under invasive mechanical ventilation with controlled ventilation (intubation or tracheotomy).
  • Patient equipped with an arterial catheter.
  • Patient sedated (BIS between 30 and 50) and, if necessary, under neuromuscular blocking agent (TOF \< 2/4 at the orbicular) to avoid inspiratory effort.
  • Patient hemodynamically optimized following the Swan-Ganz catheter data.

You may not qualify if:

  • Refusal to participate in the proposed study.
  • Unavailability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems Inc., Arjo AB)
  • Obesity with BMI ≥ 35 kg.m-2
  • Significant hemodynamic instability defined as an increase of more than 20% in catecholamine doses in the last hour, despite optimization of blood volume, for a target mean blood pressure between 65 and 75 mmHg.
  • Contraindication to the insertion of a nasogastric tube
  • Contraindication to the use of the chest electrical impedance tomography
  • Contraindication to the insertion of a Swan-Ganz catheter
  • Contraindication to the application of compression stockings
  • Patient under guardianship
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU

Clermont-Ferrand, 63000, France

Location

Related Publications (1)

  • Bouchant L, Godet T, Arpajou G, Aupetitgendre L, Cayot S, Guerin R, Jabaudon M, Verlhac C, Blondonnet R, Borao L, Pereira B, Constantin JM, Bazin JE, Futier E, Audard J. Physiological effects and safety of bed verticalization in patients with acute respiratory distress syndrome. Crit Care. 2024 Aug 5;28(1):262. doi: 10.1186/s13054-024-05013-y.

MeSH Terms

Conditions

Respiratory Distress Syndrome

Interventions

Beds

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Intervention Hierarchy (Ancestors)

Equipment and Supplies, HospitalEquipment and Supplies

Study Officials

  • Jules Audard

    University Hospital, Clermont-Ferrand

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Analysis of data will be conducted by a statistician not involved in interventions at bedside
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Interventional study evaluating the beneficial impact of verticalization of patients with ARDS on pathophysiological parameters
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2020

First Posted

May 1, 2020

Study Start

March 30, 2020

Primary Completion

January 14, 2021

Study Completion

January 14, 2021

Last Updated

August 25, 2021

Record last verified: 2020-06

Locations